title: Treatment for infections with carbapenem-resistant Enterobacteriaceae: what options do we still have?
abstract: The global spread of carbapenem-resistant Enterobacteriaceae (CRE) is increasingly becoming a major challenge in clinical and public health settings. To date, the treatment for serious CRE infections remains difficult. The intelligent use of antimicrobials and effective infection control strategies is crucial to prevent further CRE spread. Early consultation with experts in the treatment of infections with multidrug-resistant organisms is valuable in patient management. This brief review will focus on the current, yet limited, treatment options for CRE infections.
authors.forename: Michele
authors.initials: M
authors.lastname: Yamamoto
authors.forename: Aurora E
authors.initials: AE
authors.lastname: Pop-Vicas
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D015780:Carbapenems / Q000627:therapeutic use; D024881:Drug Resistance, Bacterial; D004755:Enterobacteriaceae / Q000187:drug effects* / Q000201:enzymology / Q000472:pathogenicity; D004756:Enterobacteriaceae Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology / Q000517:prevention & control; D014943:Global Health; D006801:Humans; D017053:Infection Control / Q000379:methods
chemical_list: D000900:Anti-Bacterial Agents; D015780:Carbapenems